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Gene therapy based on engineered viruses has emerged as a highly
promising and general approach to treat human disease. In particular,
recombinant vehicles or vectors based on adeno-associated viruses
(AAVs) have emerged as safe and effective gene therapy vectors.1,2
Among their favorable properties are a strong clinical safety proﬁle,
ability to promote high transgene expression in both dividing and
non-dividing cells, minimal risk of integration, and low immunoge-
nicity. As a result, AAV gene therapies have been increasingly suc-
cessful for the treatment of monogenic disorders in the liver and
retina,3,4 as well as for basic biological investigations in a broad range
of organisms.
However, efﬁcient application to a broad range of cell and tissue tar-
gets has been limited by delivery challenges that necessitate molecular
engineering of this complex, multimeric biomolecule. These prob-
lems include pre-existing neutralizing antibodies against the AAV
capsid, poor transduction of clinically and biologically important304 Molecular Therapy Vol. 26 No 1 January 2018 ª 2017 The Americcell types, infection of off-target tissues, and the need for high vector
doses. In particular, transduction of the CNS is difﬁcult due to biolog-
ical barriers that limit vector distribution.5 It is unsurprising that nat-
ural AAV serotypes suffer such shortcomings given that the selective
pressures driving natural AAV evolution are often at odds with our
needs for enhanced biological tools and/or human therapeutics. How-
ever, the AAV capsid can be engineered to overcome these challenges
through directed evolution, an iterative process of mutation and
selection for improved function that mimics natural evolution but
utilizes protein diversiﬁcation strategies and selective pressures
designed to address clinical needs. We have previously applied
AAV-directed evolution to engineer novel AAV variants for
enhanced in vivo gene delivery to the CNS6–10 and other tissues.11–14
However, intricate multimeric structures, such as the AAV capsid,
pose protein engineering challenges, including both library genera-
tion and phenotypic selection.
Optimization of directed evolution begins with the design of a library.
In particular, the goal of AAV library generation is to create a large,
diverse pool of capsid variant sequences for subsequent selection,
while minimizing the potential for disruption of the core virus func-
tions necessary for packaging, transduction, and gene expression. In
general, the majority of mutations introduced via random mutagen-
esis techniques are deleterious and lead to non-functional proteins.15
An alternative method, DNA shufﬂing, recombines naturally occur-
ring, homologous sequences into a library of chimeras in which
sequence diversity has been exchanged between functional parent
sequences.16 By shufﬂing functional sequences, a far greater number
of mutations can be introduced relative to random mutagenesisan Society of Gene and Cell Therapy.
www.moleculartherapy.org(e.g., error-prone PCR) techniques. However, it can be difﬁcult to
rationally predict the crossover locations among a family of proteins
that will be least disruptive to folding of chimeric proteins, particu-
larly in multimeric protein and protein-nucleic acid structures as
complex as ribosomes, transcriptional machinery, or viral capsids.
Moreover, traditional DNA shufﬂing methods, which typically
involve random nuclease digestion of the target sequences followed
by homology-based reassembly, are biased to place crossovers in
regions of high homology.17
SCHEMA is a computational method to predict the optimal crossover
points for DNA shufﬂing of chimeric proteins.18 This approach uses a
contact map representation of protein structures and calculates the
number of residue-residue contacts that are disrupted when homolo-
gous proteins are recombined. Libraries of chimeric proteins can be
designed by balancing the average SCHEMA disruption with the
number of mutations introduced to identify a set of crossovers that
maximizes the library’s overall functional diversity. SCHEMA has
been applied to a range of functionally diverse proteins,19–22 but
importantly the extension of SCHEMA tomultimeric proteins, which
could include cellular transcriptional complexes, translational
machinery, self-assembling structural proteins, viruses, and other
multiprotein assemblies, affords opportunities to engineer proteins
with modular structures and/or complex regulatory domains.23,24
SCHEMA can be used to design libraries that are high in theoretical
diversity, and previous studies have characterized the properties of
101–103 individual library members. Building upon these capabilities,
we harnessed AAV-directed evolution to screen millions of capsid
chimeras for improved function. One recent study used SCHEMA
to generate and characterize the in vitro properties of 17 individual
chimeras of AAV2 and AAV4, each containing a single crossover
event.25 Here, we construct a SCHEMA AAV capsid library
comprised of six parent serotypes (AAV2, AAV4, AAV5, AAV6,
AAV8, and AAV9) and seven crossover positions, yielding a total
library size of more than 1.6million variants. Moreover, we developed
a Cre-dependent selection strategy to screen the entire library and
drive convergence to chimeric AAVs that infect adult neural stem
cells (NSCs) of the subventricular zone (SVZ), a cell type of clinical
importance that is poorly transduced by natural AAV serotypes.
The SVZ of the lateral ventricles is the largest germinal region in the
adult mammalian brain.26 Resident adult NSCs of the SVZ produce
new neurons and oligodendrocytes throughout life27,28 and are
therefore an attractive experimental model to study mechanisms
of adult neurogenesis and stem cell response to brain injury and
disease. Whereas in vitro NSC culture offers opportunities for
high-throughput screening of small-molecule libraries that
modulate cell proliferation, differentiation, and toxicity,29,30 cell
culture does not fully recapitulate the rich signaling environment
of the neurogenic niche. In vivo manipulation of NSCs is thus
key to gaining a deeper understanding of the regulatory mechanisms
that contribute to NSC fate decisions and to unlocking the
potential of endogenous NSCs for therapies. However, gene delivery
to the SVZ remains challenging, and no single strategy hasenabled efﬁcient delivery while limiting disruption of the SVZ
microenvironment.31,32
Adult NSCs of the SVZ therefore represent an ideal target to evaluate
the efﬁcacy of the SCHEMA AAV library and in vivo Cre-dependent
selection strategy. Application of these advanced directed evolution
methods resulted in selection of SCH9, a SCHEMA AAV variant
that efﬁciently transduces NSCs throughout the entire SVZ in both
hemispheres after a unilateral injection into the lateral ventricle.
RESULTS
SCHEMA-Guided Design of a Chimeric AAV Library
We designed a chimeric AAV library that recombines six natural se-
rotypes (AAV2, 4, 5, 6, 8, and 9) that represent multiple phylogenetic
clades,33 have diverse receptor binding properties,1 and have enjoyed
some success in the clinic.2 We used the capsid crystal structures to
calculate contacting intra- and inter-subunit residue positions,
wherein a contact was deﬁned as two residues containing nonhydro-
gen atoms within a spatial cutoff of 4.5 Å. The ﬁnal contact map con-
tained residue pairs that were contacting in at least 50% of these six
parent structures. To achieve high library diversity, we aimed to
design a library containing six crossovers within the crystallized
region of the capsid and a seventh in the uncrystallized VP1 region
(amino acids 1–216) at position 128 based on a previous example
of successful recombination at that location.34 A library containing
eight capsid protein blocks from six parent serotypes yields a theoret-
ical library diversity of more than 1.6 million (68) chimeric variants.
We additionally modiﬁed the SCHEMA scoring function to search
for crossover locations that were amenable to combinatorial golden
gate assembly for library construction, which requires 4-nt stretches
that are conserved across all AAV parent sequences. In order to
increase the number of possible crossovers sites, and thereby probe
a larger sequence space in silico, we included 4-nt stretches that could
be silently mutated during library assembly to be identical in all
parent sequences.
After specifying these design parameters, we applied the RASPP
method (Recombination as a Shortest Path Problem)35 to rapidly
identify 160 of the least disruptive library designs (sets of seven cross-
over positions) over a range of mutation levels. For each of these
designs, the average library disruption score hEi and number of
amino acid mutations introduced hmi relative to the closest parent
serotype were calculated (Figure 1A), and the crossover locations of
all RASPP designs are presented in Figure 1B. A ﬁnal design with
an average disruption score hEi of 59 and average number of muta-
tions hmi of 82 per subunit in the crystallized region of the capsid
(Figures 1A–1C) was chosen for several reasons. First, this design
was in a cluster of RASPP libraries (Figure 1A) that represented a rela-
tive minimum in hEi at high mutation levels. Second, the selected
design shufﬂed key capsid structural features, which include sur-
face-exposed loops and hypervariable regions that represent the
most divergent regions in the evolution of natural AAV serotypes
(Figure 1C). Recombination within these contact-rich regions results
in greater disruption, but is also more likely to generate AAVMolecular Therapy Vol. 26 No 1 January 2018 305
Figure 1. SCHEMA AAV Library Design
(A) The RASPP optimization algorithm generates library designs that are lower in hEi at variousmutation levels. The RASPP library design selected for construction is indicated
in red. (B) RASPP library designs over a range of hEi levels. The library selected for construction is indicated by a black border. Block 1 is omitted because it lies outside of the
crystallized region of the capsid for which the SCHEMA analysis can be conducted. Parameters for library design were a minimum block length of 20 amino acids and a
maximum length of 250 amino acids. (C) Schematic of cap crossover positions in the AAV library design selected for construction. An alignment of capsid loops, b strands that
form the anti-parallel b-barrel motif, hypervariable regions (HVR), and the assembly-activating protein (AAP) are provided to indicate known structure-function relationships in
the AAV capsid. (D) Protein contact map of the selected library design. All possible residue-residue contacts are displayed as black dots. The colored squares represent the
sequence blocks that are shuffled. Contacts retained within the colored squares are preserved during recombination, while contacts outside of these squares may be broken
depending on the identity of the parent sequences at each block. (E) Three-dimensional models of the selected capsid design. The shuffled blocks are represented by the
corresponding colors used in (B)–(D) and mapped onto the AAV2 crystal structure (PDB: 1LP3) in PyMOL. The full biological assembly and a single asymmetric subunit with
shapes indicating the axes of symmetry are shown. (F) The percentage frequency of each AAV parent before and after viral packaging of the assembled SCHEMA library are
presented as a heatmap.
Molecular Therapychimeras with new and interesting functions. For example, signiﬁ-
cantly lower disruption scores could be achieved by combining blocks
5 and 6, but doing so would generate capsids with surface-exposed306 Molecular Therapy Vol. 26 No 1 January 2018loop regions derived from a single parent sequence. Finally, this set
of crossover positions was selected because it provided a relatively
even distribution of block sizes. We programmed RASPP to consider
www.moleculartherapy.orga range of permissible block sizes from 20 to 250 amino acids. The
majority of the lowest hEi designs contained two long blocks (>175
amino acids for blocks 3 and 4) followed by a series of short blocks
(<30 amino acids for blocks 5–7) (Figure 1B). In contrast, our chosen
set of crossover positions (Figure 1C) offers a more even distribution
of block sizes, ensuring shufﬂing throughout the capsid as opposed to
conﬁning crossovers within a few regions that are of limited diversity
in the parent sequences.
The selected library design was assembled by combinatorial golden
gate cloning,36 electroporated into E. coli to yield over 5  106 trans-
formants, and packaged into AAV virions. The frequency of parent
serotypes at each block position was analyzed by deep sequencing
before and after viral packaging (Figure 1F). We found that each
parent serotype sequence was well represented and distributed at
each block location prior to viral packaging, but packaging presum-
ably imposed a signiﬁcant selective pressure for stable capsids and
thereby resulted in substantial changes in library composition. For
example, the frequency of AAV4 and AAV5 decreased by an average
of 348- and 372-fold, respectively, across the packaged library, likely
because of the low average amino acid sequence identity (AAV4: 60%,
AAV5: 65%) of these serotypes with the other AAV parents used for
library assembly. Changes in library composition upon packaging
were also reﬂected in the decrease in the average disruption score
hEi per crystallized subunit from 59 to 4 and in the average number
of mutations hmi from 82 to 28. In agreement with prior applications
of SCHEMA,19,37 lower hEi chimeras were thus heavily enriched in
the library. Interestingly, we also observed a preference for AAV2
at blocks 5 and 6 and AAV9 at block 8, trends that could be consid-
ered in the future to guide rational capsid engineering.
A Cre-Dependent Selection Strategy for AAV-Directed Evolution
Library diversiﬁcation generates millions of mutant capsids, each a
possible solution to a therapeutic gene delivery challenge. It is there-
fore crucial to design a stringent directed evolution strategy that can
rapidly drive convergence from millions of variants to optima in a
ﬁtness landscape. NSCs are an especially difﬁcult target given that
they are rare cells that reside in a small niche within a complex tissue
protected by biological barriers, including the ependymal cell layer
lining the ventricle and the blood-brain barrier. NSCs can be isolated
and cultured as neurospheres, but in vitro culture poorly recapitulates
the spatial organization of the three-dimensional niche, its cell-cell
interactions, the extracellular environment, and access to the cerebro-
spinal ﬂuid (CSF) and vasculature. It would thus be advantageous to
conduct evolution in vivo. However, in vivo-directed evolution stra-
tegies typically rely on extraction of genomic DNA from whole tissue
and PCR to amplify the target gene, methods that are not selective for
any particular cell type and may result in false positives that are en-
riched through transduction of cells that form biological barriers
(e.g., ependymal and endothelial cells). To speciﬁcally target NSCs,
we designed an in vivo Cre-dependent directed evolution and selec-
tion strategy to drive positive selection of AAV variants that infect
NSCs in the SVZ. A conceptually analogous but distinct Cre-depen-
dent system was reported during the course of this study.38More than 300 transgenic mice that drive Cre expression under the
control of a cell-type-speciﬁc promoter have been developed.39 We
harnessed the cell-type speciﬁcity of Cre expression to mediate selec-
tive recovery of the AAV cap gene by ﬂanking the cap gene with a pair
of loxP sites. AAV infection of a Cre-expressing cell followed by sec-
ond-strand AAV genome synthesis leads to the inversion of the ﬂoxed
cap, and PCR primers that serve as a forward and reverse pair only in
the inverted gene template are used to selectively recover the Cre-in-
verted cap genes from the brain tissue (Figures 2A and 2B). Mutant
loxP sites lox66 and lox7140 were utilized to drive the equilibrium
of Cre recombination toward unidirectional inversion. We initially
attempted to insert the loxP sites in the 30 UTR of cap, where they
ﬂanked short stuffer sequences containing the target sequence for
the reverse primer used for Cre-dependent recovery. We found that
recombination occurred at low levels during bacterial plasmid prop-
agation, even in Sure2 recombinase-deﬁcient E. coli (Figure S1). To
prevent this undesired recovery of inverted cap during in vivo selec-
tions, we repositioned the loxP sites to ﬂank cap such that artifactual
inversion during bacterial propagation of the vector plasmid library
would result in an inverted cap sequence that does not encode viral
proteins and thus would not subsequently package in 293 cells, a pro-
vision not included in an alternate design.38 Note that insertion of
loxP sites ﬂanking the cap gene alters the reading frame of the rep
gene. The translation initiation codons of rep were thus removed,
the viral promoter that drives cap expression was maintained (Fig-
ure 2A), and rep was instead supplied in trans for viral packaging
by transient transfection of a separate rep-encoding helper. These
modiﬁcations to the viral packaging plasmids resulted in a high
AAV viral genomic yield as quantiﬁed by qPCR (Figure 2C).
Adult NSCs in the SVZ express glial markers including glial ﬁbrillary
acidic protein (GFAP),28 glutamate aspartate transporter (GLAST),41
and brain lipid-binding protein (BLBP).42 To select for adult NSC
transduction, we utilized the GFAP-Cre 73.12 mouse line in which
Cre recombinase expression is controlled by the mouse GFAP pro-
moter. Cre expression is observed in adult GFAP-expressing NSCs
and mature astrocytes.43 Although Cre is expressed in astrocytes in
addition to NSCs, the intracerebroventricular (i.c.v.) route of admin-
istration results in preferential transduction of the SVZ where the
NSCs reside, and GFAP serves as an important marker of NSC iden-
tity.28 To validate Cre-dependent recovery of cap, we delivered AAV
libraries containing ﬂoxed cap genes (pSub2FloxCap) to GFAP-Cre
73.12 or C57BL/6J control mice through an i.c.v. injection. Inverted
cap could only be ampliﬁed from brain tissue of mice expressing
Cre, while non-inverted cap was present in both groups (Figure 2D).
For Cre recombination to occur, the AAV genomemust be in double-
stranded form, as required for expression of a therapeutic transgene.
It is therefore likely that the non-inverted pool of cap genes ampliﬁed
from the GFAP-Cre 73.12 mice represents capsids that failed to infect
GFAP-positive cells, were defective in some aspect of the viral life
cycle (e.g., capsid uncoating, endosomal escape), or did not complete
second-strand synthesis. The Cre-dependent selection strategy thus
exclusively recovers capsid variants that complete all steps necessary
for robust transgene expression in the target cell type.Molecular Therapy Vol. 26 No 1 January 2018 307
Figure 2. Design of a Cre-Dependent Selection Strategy for AAV-Directed Evolution
(A) Modifications to the AAV viral genome enable Cre-dependent selection. Mutant loxP sites lox66 and lox71 flank the cap gene. Upon Cre inversion of cap, primer ISF
changes from a reverse primer to a forward primer, and primer NSF changes from a forward primer to a reverse primer. Primer R remains a reverse primer. Amplification of
inverted cap is achieved using the primer pair ISF and R, whereas primers NSF and R selectively amplify non-inverted cap. The translation initiation codons for the Rep open
reading frames are knocked out. (B) Cre-dependent AAV selection strategy to target adult neural stem cells. AAV libraries were generated through DNA shuffling or other
methods, packaged into AAV virions, and administered to GFAP-Cre 73.12 mice through a unilateral i.c.v. injection. Three weeks later, genomic DNA was extracted from
brain tissue of the contralateral hemisphere, and inverted cap variants were selectively amplified using the primers ISF and R for the next round of selection. (C) Viral genomic
titers are not significantly different when rep is supplied in trans to package wild-type AAV2. Data are presented as mean ± SEM; n = 3. (D) Selective amplification of inverted
cap from GFAP-Cre mice. NS, not significant.
Molecular TherapyIn Vivo Library Selections Converge on a Dominant SCHEMA
AAV Variant
After validating Cre-dependent recovery of cap, we initiated in vivo
selections using an equimolar mixture of six AAV libraries, each
containing 106–107 unique variants: (1) the new SCHEMA AAV;
(2) error-prone AAV9; (3) ancestral AAV;44 (4) shufﬂed AAV
generated by DNase I digestion and reassembly of AAV1, 2, 4, 5,
6, 8, and 9;12 (5) error-prone AAV2;45 and (6) AAV2 7-mer peptide
insertion at amino acid 588.46 Libraries 3–6 have previously yielded
highly infectious clones in our directed evolution selections9–12,44
and provide evolutionary competition for the SCHEMA library.
The libraries were combined and injected via i.c.v. administration
into the right lateral ventricle of adult GFAP-Cre mice (n = 3) to
transduce NSCs throughout the entire SVZ in both hemispheres.
In contrast, direct SVZ injection is more disruptive to the local tis-
sue and could require multiple injections to cover the same tissue
volume.
Three weeks after injection the contralateral brain hemisphere was
harvested, genomic DNA was extracted, and Cre-recombined AAV
cap variants were recovered from GFAP-expressing cells by PCR.308 Molecular Therapy Vol. 26 No 1 January 2018The contralateral hemisphere was harvested to ensure that cap vari-
ants were not recovered from transduction associated with the injec-
tion tract through the cortex superior to the lateral ventricle. After
three rounds of in vivo selection, Sanger sequencing analysis of 24
clones revealed convergence on two variants originating from the
SCHEMA library. SCH9 (chimera 6, 9, 8, 9, 9, 2, 9, 9; hEi 9,
hmi 49) represented 54% of the clones recovered, whereas SCH2
(chimera 6, 9, 8, 9, 2, 2, 9, 9; hEi 4, hmi 37) represented 33%. The re-
maining clones were derived from the AAV2 7-mer insertion (8%)
and ancestral libraries (4%). SCH9 differs from the closest parent,
AAV9, by 58 total mutations (92% amino acid identity). 49 of these
(hmi) are in the crystallized region of the capsid, and 9 are in the un-
crystallized region. An amino acid alignment of sequences of SCH9,
SCH2, and multiple parent AAV serotypes are presented in
Figures S2 and S3, respectively. The two SCHEMA variants differ
only at block 5, resulting in a difference of 18 amino acids. A model
of the three-dimensional structure of SCH9 shows AAV9 at loop
VR-IV on the capsid surface, AAV2 at loops V–VIII, and AAV8 at
the 5-fold pore structure (Figure 3). Based on these intriguing
features, and its dominance of the selected pool, we chose to focus pri-
marily on in vivo characterization of SCH9.
Figure 3. Three-Dimensional Models of the SCH9 Capsid
Block boundaries are represented on a schematic of the cap gene. Each parent
serotype is represented by a different color (AAV9: red, AAV8: yellow, AAV2: purple)
and mapped onto the AAV9 crystal structure (PDB: 3UX1) in PyMOL. (A and B) The
full biological assembly (A) and a single asymmetric subunit (B) with shapes indi-
cating the axes of symmetry are shown. Residues involved in heparin or galactose
binding are annotated in green and blue, respectively, on the individual subunit.
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To assess the transduction proﬁle of SCH9 in the SVZ, we successfully
packaged (recombinant AAV packaging yields are reported in Fig-
ure S4) and delivered recombinant AAV (rAAV) carrying a self-com-
plementary CAG-GFP cassette to the right lateral ventricle of adult
C57BL/6J mice. SCH9 was benchmarked against AAV9 because of
its broad use in the CNS and capacity to transduce the brain paren-
chyma from the CSF after intrathecal injection.47,48 Moreover,
of the natural serotypes, AAV9 is the most closely related sequence
to SCH9.
Transduction of the contralateral hemisphere was analyzed 4 weeks
after injection, and GFP expression was primarily associated with
the region surrounding the ventricle, with greatest intensity in the
SVZ (Figure 4A). Transduction efﬁciency was evaluated by both the
intensity of GFP expression and the total volume of the SVZ that
was positive for GFP. The integrated GFP ﬂuorescence intensity for
SCH9 was 24-fold higher, and GFP was expressed in a 12-fold greater
SVZ transduction volume, compared to AAV9 (Figures 4B and 4C).
The SVZ is composed of multiple cell types including ependymal
cells, adult NSCs (B cells), transit amplifying cells (type C cells),neuroblasts (type A cells), and mature astrocytes.26 To evaluate
the efﬁciency of NSC transduction in the SVZ, we ﬁrst assessed
molecular markers that are selectively expressed within NSCs.
Although most markers are expressed in multiple cell types in
the SVZ, reﬂecting the continuum of gene expression during line-
age progression, vascular cell adhesion molecule 1 (VCAM1) spe-
ciﬁcally localizes to the endfeet of NSCs that contact the ventricle.49
As an initial characterization, we found GFP/GFAP/VCAM1-posi-
tive adult NSCs that were transduced by SCH9 in the SVZ
(Figure 4D).
Recombinant AAV genomes are maintained episomally and are pro-
gressively lost during the cell divisions characteristic of adult neuro-
genesis in the SVZ. Speciﬁcally, lineage progression from a NSC to an
olfactory bulb interneuron involves over seven cell divisions.50 As a
result of the accompanying AAV genome dilution, at late time points
after injection the majority of cells that continue to express transgene
are slowly dividing NSCs or post-mitotic cells. Moreover, prior
studies using integrating retroviral vectors indicate that the time
required for neuroblasts to traverse the rostral migratory stream to
the olfactory bulb is 9 days, and that all transit amplifying cells and
neuroblasts present in the SVZ at the time of injection differentiate
and/or migrate to the olfactory bulb and established dendrites by
30 days post-injection.51,52 These results indicate that neuroblasts
present in the rostral migratory stream at late time points after injec-
tion are derived from NSCs, a conclusion that was previously used to
establish lentiviral or non-viral transduction of NSCs in the SVZ.53,54
We designed a similar lineage analysis strategy to determine the num-
ber of migrating neuroblasts expressing tdTomato 30 days post-injec-
tion as an indication of NSC transduction. Recombinant SCH9 or
AAV9 encoding Cre recombinase was injected into the right lateral
ventricle of adult Ai9 ﬂoxed STOP tdTomato mice,55 within which
Cre activity would result in tdTomato expression in transduced
cells and their progeny. The majority (injected right hemisphere
83.2% ± 3.6%, left hemisphere 50.3% ± 4.4%) of neuroblasts were pos-
itive for tdTomato in the rostral migratory stream 30 days post-injec-
tion of SCH9-expressing Cre (Figures 4E and 4G), exceeding AAV9
transduction by more than 4-fold. Furthermore, large numbers of
tdTomato-positive neuroblasts were observed migrating radially in
the olfactory bulb and adopting the morphology of granule cell
neurons (Figure 4F).
To further characterize NSC transduction, we administered the
thymidine analog BrdU (5-bromo-20-deoxyuridine) to label dividing
cells in the SVZ prior to injection of single-stranded SCH9 CAG-Cre.
After a washout period of 2 weeks, we analyzed colocalization of
tdTomato expression with BrdU incorporation into GFAP+ NSCs
(Figure 4H). The percentage of adult NSCs (GFAP+, BrdU+,
doublecortin), transit amplifying cells (GFAP, BrdU+,
doublecortin), and neuroblasts (GFAP, BrdU+, doublecortin+)
expressing tdTomato in the SVZ were quantiﬁed (Figure 4I). Approx-
imately 60% of NSCs were transduced in both hemispheres, support-
ing the efﬁcacy of SCH9 for gene delivery to NSCs using both
single-stranded and self-complementary genome formats.Molecular Therapy Vol. 26 No 1 January 2018 309
Figure 4. SCH9 Efficiently Transduces Neural Stem Cells in the Subventricular Zone
(A) SCH9 strongly transduces the SVZ contralateral to the injection site. Coronal sections were stained for GFAP (red) and GFP (green). Scale bars indicate 100 mm. (B and C)
SCH9 mediates higher GFP fluorescence intensity (B) and transduction volume (C) in the SVZ than AAV9. Data are presented as mean ± SEM; n = 3. Statistical difference of
*p < 0.005 by two-tailed Student’s t test. (D) Neural stem cells infected with SCH9 express GFP (green) and the neural stem cell markers GFAP (red) and VCAM1 (blue) in
coronal sections. Scale bar indicates 20 mm. (E) Labeling of tdTomato-positive migrating neuroblasts in the SVZ-RMS-OB pathway 30 days post-injection of SCH9 (top) or
AAV9 (bottom) expressing Cre recombinase in Ai9 floxed STOP tdTomato mice. Sagittal sections were stained for the neuronal migration protein doublecortin (DCX, green),
and tdTomato fluorescence (red) is native. Dashed rectangles indicate the region of the rostral migratory stream that is magnified in the right panels. Scale bars indicate
200 mm. (F) TdTomato-positive neuroblasts in multiple stages of radial migration and differentiation into granule cells were observed in the olfactory bulb (top: SCH9,
bottom: AAV9). Sagittal sections were stained for DCX (green), and tdTomato fluorescence (red) is native. Scale bars indicate 200 mm. (G) SCH9 transduction results in a
higher percentage of DCX+/tdTomato+ neuroblasts in the rostral migratory stream than with AAV9. Data are presented as mean ± SEM; n = 4–5. Statistical difference of
*p < 0.005 by two-tailed Student’s t test. (H) Representative images of marker colocalization with BrdU+ cells. Sagittal sections were stained for DCX (green), GFAP (blue),
BrdU (cyan), and tdTomato (red). Scale bar indicates 50 mm. (I) Quantification of BrdU+/GFAP+ NSCs in the left and right hemispheres. Data are presented as mean ± SD;
n = 5. CC, corpus callosum; LV, lateral ventricle; OB, olfactory bulb; RMS, rostral migratory stream; SVZ, subventricular zone; Str, striatum.
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Figure 5. SCH9 Mediates High Transduction of
Purkinje Cells in the Cerebellum
(A) Representative images of the cerebellum 30 days after
injection of recombinant AAV9 and SCH9 expressing Cre
to activate tdTomato (red). Sagittal sections were stained
for the Purkinje cell marker calbindin (green), and
tdTomato fluorescence is native. Scale bars indicate
200 mm. (B) Integrated intensity of tdTomato fluorescence
in calbindin-expressing Purkinje cells. Data are presented
asmean ±SEM; n = 4–5. Statistical difference of *p < 0.05
by two-tailed Student’s t test. (C) Percentage of calbindin-
positive cells expressing tdTomato. Data are presented
asmean ±SEM; n = 4–5. Statistical difference of *p < 0.05
by two-tailed Student’s t test.
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Capsid mutations that enhance infection of the target cell type can
simultaneously improve transduction in other regions of the brain.
Although SCH9 transduction following i.c.v. injection was primarily
associated with the SVZ, we also observed increased reporter expres-
sion in Purkinje cells of the cerebellum, a region of the brain directly
accessible to vector circulating in the CSF (Figure 5A). Purkinje cells
are a key target of gene therapies for neurodegenerative diseases
including spinocerebellar ataxias.56 Delivery of SCH9-Cre activated
tdTomato reporter expression that was 12.2-fold more intense and
covered 9.3-fold greater calbindin-positive area than AAV9-Cre (Fig-
ure 5B) as quantiﬁed by CellProﬁler.
The success of SCH9 in transducing Purkinje cells from the CSF
suggests its potential as a gene delivery vector for the cerebellum.
Cerebellar gene therapies have employed rAAV delivery to the deep
cerebellar nuclei, amajor hub in cerebellar circuitry that receives inhib-
itory inputs from Purkinje cells.57,58 By harnessing this circuitry, a sin-
gle injection of rAAV into thedeep cerebellar nuclei can transducePur-
kinje cells throughout the cerebellar cortex through retrograde
transport of the vector. We compared transduction patterns of SCH9
with AAV1, the most commonly used serotype for gene delivery to
the cerebellum, after unilateral injection into the deep cerebellar nuclei
of the right hemisphere (Figure S5). Both vectors supported strong
transduction of Purkinje cells throughout the cerebellum in the ipsilat-
eral hemisphere, indicating that SCH9 can be transported in the retro-
grade direction. Finally, we evaluated the tropism of SCH9 and AAV1
after direct injection into the striatum (Figure S6). SCH9 (80.7%
neurons, 19.3% astrocytes, SD 2.6%) and AAV1 (84.6% neurons,
15.4% astrocytes, SD 1.5%) were similarly neurotropic.MoleSCH9 Can Utilize Both Heparan Sulfate
Proteoglycans and Galactose for Cell
Transduction
Given the promising infectious properties of
SCH9, we next examined whether its chimeric
nature may have conferred a selective advantage
to SCH9 by modulating the receptor binding
capabilities of its multiple parent serotypes.
Block 6 of SCH9 contains the heparin bindingpocket of the AAV2 capsid.59 In addition, blocks 2 and 5 contain
the galactose binding residues D271, N272, N470, and Y446 of
AAV9, whereas block 6 conserves residue W503.60 In contrast,
SCH2 lacks two of the key galactose-binding residues because of sub-
stitution of AAV2 for AAV9 at block 5.
We ﬁrst employed chromatography to demonstrate that the heparin
afﬁnity of both SCHEMA variants was comparable to AAV2, indi-
cating that the chimeric sequence context outside of the heparin
pocket did not signiﬁcantly inﬂuence binding afﬁnity (Figure 6A).
We next evaluated the potential for dual utilization of heparan sulfate
proteoglycans (HSPG) and galactose by infecting CHO-Lec2 cells that
express terminal galactose residues and HSPG on the cell surface. As
previously described,61 addition of Erythrina cristagalli lectin (ECL)
blocks terminal galactose, whereas virus incubation with soluble hep-
arin competitively inhibits AAV serotypes that utilize HSPG for cell
entry. As expected, the AAV2 and AAV9 control vectors utilized
HSPG and galactose, respectively. Interestingly, SCH2 was solely
dependent on HSPG, whereas SCH9 was able to use both HSPG
and galactose, and actually required that both be blocked to prevent
cell transduction (Figure 6B). After characterizing the different
glycan-binding properties of SCH2 and SCH9, we examined whether
both variants retained utilization of AAVR, a newly described protein
receptor that is critical for AAV infection in natural AAV serotypes.62
SCH2, SCH9, and the AAV2 control were all clearly dependent on
AAVR (Figure S7).
Finally, because DNA shufﬂing has been shown to disrupt neutral-
izing antibody epitopes,14,63 we quantiﬁed the resistance of SCH9 to
human intravenous immunoglobulin (IVIG), a polyclonal mixturecular Therapy Vol. 26 No 1 January 2018 311
Figure 6. Characterization of SCH9 Glycan Binding
and Resistance to Neutralizing Antibodies
(A) SCH9 and SCH2 bind a heparin column with similar
affinity as AAV2. Samples were loaded onto a heparin
affinity column and eluted with increasing NaCl concen-
tration. The load fraction represents the virus recovered in
the column flow-through after sample loading in 150 mM
NaCl. Data are represented as mean ± SD; n = 3.
(B) SCH9 utilizes both galactose and heparan sulfate
proteoglycans for cell entry. Both HSPG and galactose
receptors must be blocked to prevent SCH9 infection of
Lec2 cells. The controls AAV2 and AAV9 utilize HSPG and
galactose, respectively. A modest decrease in infectivity
was observed after addition of ECL in all samples,
potentially because of steric blocking of receptors on the
cell surface. Data are presented as mean ± SEM; n = 3.
Statistical difference of *p < 0.005 by two-tailed Student’s
t test. (C) SCH9 is less susceptible to neutralizing anti-
bodies than the parent serotypes AAV2, AAV6, AAV8,
and AAV9. Data are presented after being normalized to
the fraction of GFP-expressing cells in the absence of IVIG
as mean ± SEM; n = 3.
Molecular Therapyof antibodies against natural AAV serotypes. We found that the anti-
body titer required to neutralize SCH9 was 2- to 10-fold higher
(Table S1) than the parent sequences from which it is derived (Fig-
ure 6C). Notably, the greatest fold improvement was relative to
AAV9, the most closely related parent sequence.
DISCUSSION
Signiﬁcant progress has been made in elucidating the molecular
mechanisms that govern NSC maintenance and neurogenesis in the
SVZ, yet the ability to genetically manipulate endogenous stem cell
populations in situ remains challenging because of inefﬁcient vehicles
for gene delivery. To overcome the challenges of transducing NSCs
in vivo and to broadly address the need for better AAV vectors, we
ﬁrst developed improved technologies for AAV-directed evolution.
The SCHEMA scoring algorithm was applied to the multimeric
AAV capsid to generate a large library of chimeric variants with
unique functional properties. A novel variant, SCH9, was selected
from this library using a Cre-dependent strategy and shown to efﬁ-
ciently infect NSCs within the SVZ. This work further establishes
the importance of library design and targeted selection strategies
for directed evolution, and provides a new tool for manipulation of
NSCs in the SVZ.
Our results demonstrate that SCHEMA-guided recombination of the
AAV capsid yields chimeric variants that meet or exceed the efﬁcacy
of parent serotypes. SCHEMA library design simultaneously mini-
mizes structural disruption while maximizing sequence diversity,
two objectives that are infeasible for randomized gene recombination
methods. Moreover, the number of mutations introduced far exceeds
the diversiﬁcation achieved with standard mutagenesis techniques
including error-prone PCR and peptide insertion. By utilizing the312 Molecular Therapy Vol. 26 No 1 January 2018high throughput of AAV-directed evolution, we screened the largest
SCHEMA library constructed to date. SCHEMA variants that pack-
age efﬁciently and incorporate sequence elements from multiple
AAV parents may represent new starting points in the protein ﬁtness
landscape that are promising templates for additional mutagenesis
and selections.
In addition to yielding infectious clones, the deﬁned locations of
crossovers in the SCHEMA library permit identiﬁcation of block mo-
tifs with desirable properties and assessment of sequence-function re-
lationships.64 For example, although the library design shufﬂes blocks
2 through 4 that span the alternative open reading frame of the
204-amino-acid-long nonstructural assembly-activating protein
(AAP), we did not observe enrichment of consecutive blocks from
the same parent serotype within this AAP region. AAP promotes
capsid formation in the nucleus, but recent evidence suggests that it
is not essential for capsid assembly of AAV4 and AAV5, and that
AAPs enable promiscuous cross-packaging of other serotypes.65,66
Indeed, we found that overexpression of AAPs from all six AAV par-
ents during packaging did not signiﬁcantly rescue AAV4 or AAV5
blocks in the library (data not shown). Interestingly, Ho et al.25
showed that their sample of AAV2/AAV4 SCHEMA chimeras with
crossovers in AAP were less likely to assemble into genome-contain-
ing capsids. These contrasting outcomes may result from the signiﬁ-
cant differences in number of parent sequences, crossover locations,
and/or library size.
We also found that incorporation of capsid loop structures from both
AAV2 and AAV9 conferred dual heparin and galactose afﬁnity to
SCH9. Both of these glycans are present on NSCs. Speciﬁcally,
HSPG function as co-receptors for the binding of key NSC growth
www.moleculartherapy.orgfactors including FGF-2 andWnt.67 Also, LewisX, a glycan motif con-
taining b1-4-linked galactose, is commonly used to isolate neural
stem and progenitor cells from the mouse brain68 and is enriched
in undifferentiated NSCs.69 The presence of HSPG and galactose on
NSCs may contribute to SCH9 transduction, although the low infec-
tivity observed with AAV9 indicates that galactose binding alone is
not sufﬁcient. Interestingly, AAV2g9, a rationally designed variant
of AAV2 with the galactose binding residues of AAV9 replacing the
corresponding residues on the AAV2 capsid, exhibits higher trans-
gene expression in murine cardiac and muscle tissues than AAV2.61
The improved infectious properties of SCH9 and AAV2g9 suggest
that engineering dual glycan binding is a promising approach to
increase vector potency.
In the course of completing our selections, a similar Cre-dependent
selection strategy was reported to select a variant of AAV9 that
crosses the blood-brain barrier more efﬁciently,38 highlighting the
effectiveness of this technique in overcoming challenging biological
barriers. This innovative work positioned loxP sites in the 30 UTR
of cap, a location that we had initially tested but found to result in
low levels of incidental recombination during bacterial propagation
even in recombinase-deﬁcient E. coli. We mitigated the likelihood
of false positives by introducing loxP sites that ﬂank the cap gene
such that artifactual recombination prevents translation of functional
capsid proteins.
Cre-dependent recovery of cap variants offers several advantages over
other selection strategies for targeting speciﬁc cell populations in the
CNS. Fluorescence-activated cell sorting of brain tissue is challenging
due to the dense packing of multiple cell types, interconnected cellular
processes that are sensitive to shear forces, and large sample sizes that
require long sorting times.70 Magnetic-activated cell sorting is more
suitable for processing the entire brain tissue, but is highly dependent
on the afﬁnity and speciﬁcity of antibodies for a target cell type. Cre-
dependent recovery can be performed after simple bulk tissue homog-
enization, reducing the number and complexity of post-mortem pro-
cessing steps that can contribute to degradation of AAV episomes.
Furthermore, Cre enforces additional stringency by requiring the
AAV capsid to trafﬁc to the nucleus, uncoat, and convert the sin-
gle-stranded genome to a double-stranded form before inversion
can occur. Importantly, these are the same criteria that are necessary
for expression of a therapeutic transgene. Hundreds of transgenic Cre
mouse strains are commercially available,39 highlighting the broad
applicability of this strategy to target a variety of cell types and tissues.
Additionally, a GFP-dependent Cre recombinase has recently been
developed,71 further expanding the utility of this system to transgenic
GFP reporter mice, of which there are over 1,300 labeling speciﬁc cell
populations in the CNS.72 Finally, intersectional strategies using two
recombinase systems (Cre/loxP and Flp/FRT)73 could be developed to
further specify a cell type of interest for positive selection. Collectively,
these strategies have strong potential for selections targeting speciﬁc
cell types within tissues. However, an important limitation is that
capsid variants selected in mice may not be effective in larger animal
models because of species-speciﬁc differences.9AlthoughCre-dependent selections impose a stringent positive selective
pressure, the resulting variants have the potential to transduce off-target
cells. Such additional expression may have therapeutic relevance, as in
the transduction of the cerebellum described in this work. However,
as required for a given application, gene expression may be further
restricted by additional mutagenesis and screening for detargeted
clones, or by inclusion of a cell-type-speciﬁc promoter in the expression
cassette. For example, a minimal GFAP promoter, which could further
restrict expression to NSCs and astrocytes, has been developed.74
Natural AAV serotypes have been considered for gene delivery to the
SVZ in vivo, because of the limitations of non-viral-,54,75,76 adeno-
viral-,77 retroviral-,78 and lentiviral-based53 methods. AAV2 exhibits
poor NSC transduction following direct injection into the SVZ.79
AAV4 displays selective tropism for ependymal cells after delivery
into the lateral ventricle, while injection directly into the SVZ results
in transduction of mature astrocytes.80 Interestingly, AAV4.18, an
engineered mutant of AAV4 with afﬁnity for 2,8-linked polysialic
acid (PSA), selectively infects migrating progenitors after i.c.v. injec-
tion in neonatal mice.81 Although this study did not examine the
tropism of AAV4.18 in adult mice, it may exhibit preferential tropism
for type A neuronal precursors that strongly express PSA-NCAM, a
polysialylated glycoprotein that is not expressed on adult NSCs or
transit amplifying progenitor cells during adult neurogenesis.82
Finally, direct injection of AAV1 into the SVZ results in efﬁcient
transduction of transit amplifying cells and neuroblasts, but not the
NSC population.83 Moreover, AAV1-mediated transgene expression
spanned only one-third of the SVZ, highlighting the need for
approaches that achieve widespread transduction of the SVZ from a
single vector administration.
SCH9 offers a number of advantages over the gene delivery methods
discussed above. A single i.c.v. injection promotes transduction of the
entire SVZ in both hemispheres, a signiﬁcant improvement in trans-
duction volume relative to direct injection into the SVZ. Although
i.c.v. injection creates a needle tract through the cortex superior to
the ventricle, it does not directly damage the SVZ, and there is negli-
gible impact on the contralateral hemisphere. Widespread transduc-
tion of the SVZ enables measurements of total neurogenesis, as well as
the effect of genetic modiﬁcations on downstream processes
including olfaction and response to brain injury. Moreover, SCH9
can provide spatial and temporal control of gene expression without
the need to generate bigenic animals. Finally, the transient expression
proﬁle of AAV in dividing cells of the germinal niche, distinct from
integrating viral vectors, could offer the opportunity for transient
expression of regulatory factors during stem cell fate determination
and reduce the risk of off-target cutting84 when using gene editing
tools including zinc ﬁnger nucleases, TALENs, and CRISPR/Cas9.
Future work to determine the minimal vector dose that supports
robust transduction of the SVZ can further improve the safety and
efﬁcacy of this approach.
NSCs that generate neuronal precursors have also been observed in
the SVZ of the adult human brain.85 Despite their germinal capacity,Molecular Therapy Vol. 26 No 1 January 2018 313
Molecular Therapychains of migrating neuroblasts are not observed in the human rostral
migratory stream beyond 2 years of age,86 although recent data sug-
gest that some precursors migrate into the striatum and differentiate
into interneurons in adult humans.87 Levels of neurogenesis are low
in healthy adults, but pathological conditions including stroke,88
epilepsy,89 and Huntington’s disease90 have been shown to induce
increased neurogenesis in humans, raising the possibility of therapeu-
tic intervention to further stimulate neurogenesis in response to neu-
rodegeneration. Such interventions are likely to be informed by our
understanding of molecular regulation of the murine SVZ. In addi-
tion to its role in neurogenesis, the SVZ has also been implicated as
a potential oncogenic niche for cancer stem cells that contribute to
tumor initiation and resistance in high-grade gliomas. For example,
tumor-initiating cells that are resistant to supramaximal chemo-
therapy doses have been isolated from the SVZ of glioblastoma
(GBM) patients91 and may play a key role in the high recurrence of
GBM after chemotherapy. Indeed, irradiation of the SVZ prolongs
progression-free survival in GBM patients,92 suggesting that targeted
therapeutic approaches including AAV-mediated delivery of anti-
cancer therapeutics93 to the SVZ could be effective. Moreover, AAV
vectors could be applied to knockout (KO) tumor suppressors or
overexpress oncogenes in mice to study the fundamental mechanisms
underlying primary tumor formation in the SVZ.94
In summary, we describe the development of vector engineering stra-
tegies that can be broadly applied to develop AAV variants that over-
come challenges as effective biology tools and/or clinical delivery
vehicles. The novel variant SCH9 supports gene delivery to NSCs
throughout the entire SVZ and will enable future elucidation of
molecular mechanisms underlying neurogenesis, as well as the devel-
opment of therapeutic strategies for diseases that impact the SVZ and
striatum.
MATERIALS AND METHODS
SCHEMA Library Design
A library of chimeric AAVs was designed using the SCHEMA scoring
function and the RASPP algorithm.18,35 The amino acid sequences of
AAV2, 4, 5, 6, 8, and 9 were aligned using MUSCLE95 to generate the
parent sequence alignment. We modiﬁed SCHEMA to consider both
intra- and inter-subunit amino acid contacts in the multimeric AAV
capsid, wherein a pair of residues is contacting if they contain nonhy-
drogen atoms within 4.5 Å. We used the crystal structures for AAV2
(1LP3), AAV4 (2G8G), AAV5 (3NTT), AAV6 (3OAH), AAV8
(2QA0), and AAV9 (3UX1) to calculate contacting residue positions.
The ﬁnal contact map contained residue pairs that were contacting in
at least 50% of these six parent structures. A chimeric capsid’s
SCHEMA disruption hEi is the number of contacts that contain
new amino acid combinations that are not present in any of the
parent sequences. A chimeric capsid’s hmi is the number of mutations
from the closest parent sequence.
We used the RASPP algorithm to design libraries that balance
the average structural disruption hEi and average sequence
diversity hmi. We altered the algorithm to include crossover locations314 Molecular Therapy Vol. 26 No 1 January 2018that were amenable to combinatorial golden gate assembly for library
construction. Golden gate assembly requires 4-nt stretches that are
conserved across all AAV parent sequences. In order to increase
the number of possible crossovers sites, and thereby probe a larger
sequence space in silico, we included 4-nt stretches that could be
silently mutated during library assembly to be identical in all parent
sequences. For the library design, we considered a minimum
sequence block length of 20 amino acids and maximum length of
250 amino acids. The ﬁnal library was chosen based on its low hEi,
its uniform block size, and recombination of key capsid structural
features.
SCHEMA Library Construction
In order to facilitate combinatorial golden gate cloning with the type
IIS restriction enzyme BsaI, we silently mutated all BsaI recognition
sites found in pBluescript SK (+), AAV2, 4, 5, 6, 8, and 9, by
QuikChange site-directed mutagenesis (Table S2). The 48 DNA
sequences corresponding to each shufﬂed block were PCR ampliﬁed
from the parent cap genes using PCR primers designed in j5, a DNA
assembly design automation software96 (Tables S3 and S4). Primers
were designed to incorporate silent mutations at block junctures to
facilitate golden gate cloning into the pBluescript vector backbone
(Table S5). Equimolar amounts of blocks 1–4 and 5–8 were assembled
separately and then combined in a ﬁnal golden gate reaction using
previously described methods.36 The golden gate assembly was
desalted by drop dialysis on a nitrocellulose membrane (Millipore
catalog no. VSWP02500) and then transformed into electrocompe-
tent DH10B E. coli to achieve a library size greater than the theoretical
diversity of 68 clones. The library was then subcloned from
pBluescript to the AAV packaging plasmid pSub2FloxCap using the
restriction enzymes HindIII and NotI.
The SCHEMA library, before and after packaging, was analyzed using
Illumina sequencing. A 2.5-kb fragment containing the AAV cap gene
was cut out of the pSub2FloxCap vector using the HindIII and NotI
sites and gel extracted. These gel-extracted inserts were used as inputs
to the Nextera XT DNA Sample Prep Kit (Illumina). Each sample was
barcoded using a different index primer. The resulting libraries were
quantiﬁed using a high-sensitivity Bioanalyzer chip (Agilent), a Qubit
Assay Kit (Invitrogen), and ﬁnally qPCR (Kapa Biosystems). The
average sequence fragment was 1,400 bp. The two libraries were
pooled in equimolar proportions and sequenced using a MiSeq,
version 3, 2  300 run with a 5% PhiX control spike-in. Sequencing
reads were mapped to all AAV parents using Bowtie2,97 and the spe-
ciﬁc sequence blocks present were determined considering the read
position and sequence identity to the parents.
Design of AAV Constructs for Cre-Dependent Selections
PCR primers used for construct design and ampliﬁcation of cap are
presented in Table S2. pSub2RepKO and pRepHelper were generous
gifts of Timothy Day and Dr. John Flannery of University of Califor-
nia (UC), Berkeley. pSub2RepKO, a rep KO in the AAV packaging
plasmid pSub2,14 was generated by digestion with SgraI and BamHI,
Klenow reaction, and blunt-end ligation. pRepHelper, used to supply
www.moleculartherapy.orgRep in trans during AAV packaging, was created by sequential diges-
tion of pAAV2/rh10 with PmeI and BsmI, Klenow reaction, and
blunt-end ligation. To insert the lox66 site 50 of cap, we introduced
a unique BglII site into pSub2RepKO by site-directed mutagenesis us-
ing the primers BglIIFwd and BglIIRev. Oligonucleotides Lox66Fwd
and Lox66Rev were annealed and ligated into the BglII and HindIII
sites of pSub2RepKO to form pSub2Lox66. To insert the lox71 site
30 of cap, we introduced unique XhoI and KpnI sites into pSub2Lox66
by site-directed mutagenesis with the primers XhoIFwd/XhoIRev and
KpnIFwd/KpnIRev, respectively. Oligonucleotides SOELox71Fwd
and SOELox71Rev were assembled by splice overlap extension and
ampliﬁed with Lox71Fwd and Lox71Rev. The resulting fragment
and pSub2Lox66 were digested with XhoI and KpnI and ligated to
create pSub2Flox. pSub2Flox and the AAV cap libraries used in this
selection were digested with HindIII and NotI and ligated to generate
pSub2FloxCap libraries for viral packaging.
AAV Vector Production
HEK293T cells were obtained from the American Type Culture
Collection (Manassas, VA, USA) and cultured in DMEM (GIBCO)
with 10% fetal bovine serum (Invitrogen) and 1% penicillin/strep-
tomycin (Invitrogen) at 37C and 5% CO2. AAV libraries and self-
complementary recombinant AAV vectors driving expression of
GFP or Cre recombinase under the control of a cytomegalovirus
early enhancer/chicken beta actin (CAG) promoter were packaged
in HEK293T cells as previously described.12,14 Brieﬂy, AAV vectors
were produced by triple transient transfection with polyethyleni-
mine (23966-1; Polysciences), puriﬁed by iodixanol density cen-
trifugation, and buffer exchanged into PBS with 0.001% Tween
20 (Sigma-Aldrich) by Amicon ﬁltration (UFC910024; EMD
Millipore). DNase-resistant viral genomic titers were measured by
real-time qPCR using a Bio-Rad iCycler (Bio-Rad, Hercules,
CA, USA).
In Vivo Selections and Characterization of SCHEMA AAV
Variants
Seven-week-old GFAP-Cre 73.12 (Jackson Laboratory Stock 012886),
C57BL/6J (Jackson Laboratory Stock 000664), or Ai9 tdTomato mice
(Jackson Laboratory Stock 007909) were anesthetized with isoﬂurane
and placed in a stereotaxic apparatus. An incision was made to expose
the skull, and a hole was drilled for injection. For library selections,
5 mL of an equimolar mixture of AAV libraries (1  1010 viral
genomes/mL) was stereotaxically injected into the right lateral
ventricle of GFAP-Cre mice (n = 3) at the coordinates 0.05 mm pos-
terior and 1.0 mm lateral to the bregma at a depth of 2.5 mm using a
Hamilton syringe as previously described.98 Injection coordinates
were selected using a mouse brain atlas and adjusted after test injec-
tions with 0.1% Fast Green dye (Sigma). Injection accuracy
throughout the study was conﬁrmed by reporter expression in the
choroid plexus and surrounding the contralateral ventricle. Mice
were sacriﬁced 3 weeks after injection, and brain tissue was harvested.
The hemisphere contralateral to the injection site was homogenized
on dry ice using a mortar and pestle. Homogenized tissue was di-
gested in Hirt lysis buffer with proteinase K (New England Biolabs)and RNase A (Thermo Fisher) at 55C for 3 hr, and extrachromo-
somal DNA was isolated using the Hirt method as previously
described.99 The PCR primers Cap_ISF and Cap_R were used to
amplify inverted cap, whereas primers Cap_NSF and Cap_R specif-
ically amplify non-inverted cap. The primers Internal_Cap_ISF and
Internal_Cap_R may be used for nested PCR if ampliﬁcation of in-
verted cap is challenging. After three rounds of selection, capsid
sequences were determined by Sanger sequencing (UC Berkeley
DNA Sequencing Facility), and dominant variants were digested
with HindIII and NotI and ligated into pXX2Not for recombinant
AAV packaging.
To characterize SCH9 and AAV9 in vivo, we stereotaxically injected
5 mL of self-complementary recombinant vector (1  1010 viral
genomes/mL) expressing GFP or Cre into the right lateral ventricle
of C57BL/6 or Ai9 tdTomato mice, respectively, at the coordinates
0.05 mm posterior and 1.0 mm lateral to the bregma at a depth of
2.5 mm using a Hamilton syringe. Ai9 mice received injections of
50 mg/kg BrdU (Sigma-Aldrich) for 3 consecutive days prior to injec-
tion of single-stranded SCH9 CAG-Cre. For injections of the deep
cerebellar nuclei, 4 mL of recombinant AAV vector (2  109 viral
genomes/mL) expressing GFP was stereotaxically injected into the
right hemisphere with coordinates 6.0 mm posterior and 2.0 mm
lateral to the bregma at a depth of 2.2 mm from the cerebellar surface
using a Hamilton syringe. For injections of the striatum, 3 mL of
recombinant AAV vector (6.7  108 viral genomes/mL) expressing
GFP was stereotaxically injected into the right hemisphere with coor-
dinates 0.5 mm anterior and 2.0 mm lateral to the bregma at a depth
of 3.0 mm from the cerebellar surface using a Hamilton syringe.
Animal procedures were approved by the UC Berkeley Laboratory
Animal Care and Use Committee and conducted in accordance
with NIH guidelines for animal care.
Immunohistochemistry
Mice were anesthetized by intraperitoneal injection of 100 mg/kg
ketamine and 10 mg/kg xylazine, and were transcardially perfused
with 0.9% saline followed by 4% paraformaldehyde. Brains were
post-ﬁxed overnight in 4% paraformaldehyde at 4C, washed in
PBS, and stored in 30% sucrose until they sank. Serial coronal or
sagittal sections were cut at 40 mm thickness on a Series 8000 sliding
microtome (Bright) and stored in cryoprotectant at 20C until
use. Free-ﬂoating sections were washed three times in PBS, incu-
bated with blocking solution (10% donkey serum and 1% Triton
X-100 in PBS) for 2 hr at room temperature, and stained with pri-
mary antibodies in blocking solution for 72 hr at 4C. The following
primary antibodies were used in this study: mouse anti-Calbindin
(1:2,000; ab82812; Abcam), rabbit anti-GFP (1:1,000; A-11122;
Life Technologies), goat anti-GFAP (1:750; ab53554; Abcam),
guinea pig anti-DCX (1:1,000; AB2253; EMD Millipore), rat anti-
VCAM1 (1:50; MAB2627; EMD Millipore), chicken anti-GFAP
(1:750; ab4674; Abcam), rat anti-BrdU (1:750; ab6326; Abcam),
and rabbit anti-tdTomato (1:750; 600-401-379; Rockland). After
three washes in PBS, sections were incubated with secondary anti-
bodies for 2 hr at room temperature and stained with DAPIMolecular Therapy Vol. 26 No 1 January 2018 315
Molecular Therapy(Thermo Fisher) for 10 minutes. Stained sections were washed three
times in PBS and mounted onto slides using VectaShield HardSet
Antifade Mounting Medium (Vector Laboratories).
Imaging and Analysis
Images were acquired using a Zeiss Axio Scan.Z1 or a confocal Zeiss
LSM 880 NLO AxioExaminer (UC Berkeley Molecular Imaging Cen-
ter). All image analyses were conducted on original images acquired
with equivalent settings. Data are presented as mean ± SEM, and sta-
tistical signiﬁcance was established by two-tailed Student’s t test.
To determine transduction volume in the SVZ, we quantiﬁed the sur-
face area of GFP expression in the SVZ from thresholded images us-
ing CellProﬁler100 in six coronal sections spanning the SVZ from the
anterior horn of the lateral ventricle to the anterior commissure, with
three mice per group. The total surface area was multiplied by the sec-
tion thickness (40 mm) and the distance between sections to obtain the
transduction volume. The same thresholded images were used for
quantiﬁcation of integrated intensity of GFP expression using
CellProﬁler.
To quantify the percentage of tdTomato-positive neuroblasts in the
rostral migratory stream, we applied the cell segmentation capabilities
of CellProﬁler to threshold, segment, and score doublecortin and
tdTomato-positive cell bodies in the rostral migratory stream. Mea-
surements were taken from two to ﬁve sagittal tissue sections contain-
ing the rostral migratory stream in each animal, with four to ﬁve mice
in each group. To evaluate transduction of adult NSCs, we scored the
identities of all BrdU-positive cells in the SVZ by colocalization with
tdTomato and GFAP or DCX. Counts were performed on confocal
images of every ﬁfth sagittal section spanning the SVZ in ﬁve mice
with four to ﬁve sections per animal.
To calculate the percentage of calbindin-stained area that is
tdTomato-positive, we employed a CellProﬁler pipeline to generate
a thresholded mask of the calbindin stain. This mask was applied to
the thresholded tdTomato image, and the tdTomato-positive area
was divided by the total calbindin area. The integrated intensity of
thresholded tdTomato within the calbindin mask was also recorded.
Measurements were taken from four to seven 40 mm sagittal tissue
sections spanning the cerebellum, with four to ﬁve mice in each
group.
In Vitro Characterization of SCHEMA AAV Variants
Unless otherwise noted, all cell lines were cultured in DMEM
(GIBCO) supplemented with 10% fetal bovine serum (Invitrogen)
and 1% penicillin/streptomycin (Invitrogen) at 37C and 5% CO2.
The heparin afﬁnities of SCH9, SCH2, and wild-type AAV2 were
determined as previously described.6 A 1 mL HiTrap heparin col-
umn (GE Healthcare Sciences) was equilibrated with 150 mM
NaCl and 50 mM Tris (at pH 7.5). 1  1011 puriﬁed viral genomic
particles were loaded onto the column and eluted by 50 mM step-
wise increases in NaCl up to a ﬁnal concentration of 950 mM, fol-
lowed by a 1 M NaCl wash. 10 mL of each elution was used to infect316 Molecular Therapy Vol. 26 No 1 January 2018HEK293T cells, and the percentage of GFP-positive cells was quan-
tiﬁed 48 hr after infection using a Guava EasyCyte 6HT ﬂow cytom-
eter (EMD/Millipore) (UC Berkeley Stem Cell Center, Berkeley,
CA, USA).
AAV utilization of galactose and HSPG for cell transduction was
characterized as previously described.61 CHO-Lec2 cells presenting
terminal galactose residues on their surface were obtained from the
tissue culture facility at the University of California, Berkeley and
cultured in MEM a nucleosides (GIBCO) supplemented with 10%
fetal bovine serum (Invitrogen) and 1% penicillin/streptomycin
(Invitrogen) at 37C and 5% CO2. One day after seeding, cells were
incubated at 4C for 30 min followed by a complete media change
into MEM with or without 100 mg/mL Erythrina cristagalli lectin
(ECL) (Vector Labs). Self-complementary rAAV CAG-GFP virions
were treated with soluble heparin (500 mg/mL) in PBS or mock-
treated for 1 hr and then used to infect cells at a genomic MOI of
12,000 (n = 3). After a 1 hr incubation with virus, Lec2 cells were
washed three times in cold PBS to remove unbound AAV, and the
percentage of GFP-expressing cells was quantiﬁed 72 hr after infec-
tion by ﬂow cytometry.
To analyze antibody evasion properties, we incubated SCH9, AAV2,
AAV6, AAV8, and AAV9 at 37C for 1 hr with serial dilutions of
IVIG (Gammagard Liquid 10% NDC 0944-2700-03) and then used
them to infect HEK293T cells at a genomic MOI of 8,000 (n = 3) as
previously described.44 IVIG was incubated at 56C for 30 min to
heat-inactivate complement prior to use. The percentage of GFP-ex-
pressing cells was quantiﬁed 48 hr after infection by ﬂow cytometry.
Neutralizing antibody titers were recorded as the ﬁrst IVIG concen-
tration at which a 50% or greater reduction in GFP expression was
observed.
To study dependence on AAVR, we infected wild-type HeLa or
AAVRKO cells (clone KIAA0319L, a generous gift from Dr. Jan Care-
tte, Stanford University, CA, USA) at a genomic MOI of 20,000
(n = 6) with SCH9, SCH2, or AAV2 carrying self-complementary
CAG-GFP. The percentage of GFP-expressing cells was quantiﬁed
72 hr after infection by ﬂow cytometry.
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